73 results about "Antigenic Specificity" patented technology

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and / or ameliorate autoimmune diseases.

The invention relates to a kit and a method for simultaneously detecting IL-6, IL-21 and T cell CD4 surface molecules in lymphatic tissue, and belongs to the field of biomedicine. The kit comprises a quantum dot marked with an IL-6 antibody, a quantum dot marked with an IL-21 antibody and a quantum dot marked with a CD4 antibody. The antibodies marked by the quantum dots are specifically combined with antigens in lymphatic tissues respectively; the CD4T cells have the capacity of secreting IL-6 and IL-21, and the mutual relation between the CD4T cells and IL-6 and IL-21 reflects the tissue immunocompetence. The invention provides a kit for simultaneously detecting IL-6, IL-21 and T cell surface molecules in lymphatic tissues, which positions the spatial relationship between two cell factors and T cells, calculates and analyzes corresponding fluorescence intensity and evaluates immune conditions. The kit has the advantages of high fluorescence intensity, accurate detection result, wide spectrum selection, wide applicability, stable fluorescence structure, long preservation time, high sensitivity, good specificity and the like.

The present invention inter alia relates to an antigen recognizing construct capable of binding to a Preferentially Expressed Antigen in Melanoma (FRAME) peptide, a T cell receptor having antigenic specificity for FRAME, a nucleic acid sequence encoding said antigen recognizing construct or T cell receptor, a vector comprising said nucleic acid sequence, and a host cell comprising said antigen recognizing construct or T cell receptor. The invention also relates to the antigen recognizing construct or T cell receptor, the nucleic acid sequence, vector or host cell for use in medicine or for use in detection, diagnosis, prognosis, prevention and / or treatment of a disease. Additionally, the present invention relates to a method of treating a disease as well as a pharmaceutical composition and a kit.

Disclosed are methods of isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising: inducing autologous APCs of the patient to present the mutated p53 amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated p53 amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of (i) glycine at position 13 with aspartic acid or (ii) glutamine at position 61 with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.

The invention discloses a preparation method of infiltrating lymphocytes with high proportion of neoantigen reactive T cells. The proportion of the reactive T cells with tumor neoantigen specificity can be increased without using a gene editing technology. In the TIL cell culture process, DC presents tumor neoantigen and TIL is sorted and cultured, the proportion of T cells with neoantigen reactivity in TIL is increased, the anti-tumor activity of the TIL cell preparation is enhanced, then the prepared infiltrated lymphocytes are rapidly and massively amplified, and the TIL cell preparation has the advantages that the tumor neoantigen reactivity is improved. And batch preparation of the neoantigen reactive TIL cell preparation with high reactivity to tumors is facilitated.

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

An isolated or purified T cell receptor (TCR) having antigen specificity for human p53Y220C or human p53R175H is disclosed. Related polypeptides and proteins as well as related nucleic acids, recombinant expression vectors, host cells, populations of host cells and pharmaceutical compositions are also provided. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

Provided herein are computer-implemented methods for training a computational model to predict T cell-antigen specificity and to predict T cell-antigen. Also provided is a system configured to predict T cell-antigen specificity via the computational model tangibly stored on an electronic device. The computational model is trained with a data training set, such as a sparse data training set, that is used as input.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The present invention inter alia relates to an antigen recognizing construct capable of binding to a Preferentially Expressed Antigen in Melanoma (FRAME) peptide, a T cell receptor having antigenic specificity for FRAME, a nucleic acid sequence encoding said antigen recognizing construct or T cell receptor, a vector comprising said nucleic acid sequence, and a host cell comprising said antigen recognizing construct or T cell receptor. The invention also relates to the antigen recognizing construct or T cell receptor, the nucleic acid sequence, vector or host cell for use in medicine or for use in detection, diagnosis, prognosis, prevention and / or treatment of a disease. Additionally, the present invention relates to a method of treating a disease as well as a pharmaceutical composition and a kit.

The present invention relates to an allogeneic myeloid cell, such as a macrophage, for use in therapy, such as the treatment of cancer in a human patient, wherein the allogeneic myeloid cell, such as an allogeneic macrophage, comprises at least one MHC-II complex identical to any one MHC-II complex of the human patient. This advantage is that an antigen-specific reaction of CD4 + T cells of the human patient, for example, against tumor neoantigens, can be initiated. The present invention also relates to an allogeneic myeloid cell, such as an allogeneic macrophage or an allogeneic monocyte, for use in the treatment of cancer in a human patient wherein the allogeneic macrophage or the allogeneic monocyte comprises at least one protein complex selected from the group consisting of HLA-DR, HLA-DP and HLA-DQ, said protein complexes are identical to any corresponding HLA complex of said human patient, preferably wherein the allomacrophages comprise two protein complexes selected from said group, or even wherein the allomacrophages comprise three complexes selected from said group.

Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.

Disclosed are methods of treating or preventing cancer in a mammal, the method comprising: (a) isolating T cells from a tumor sample from the mammal, wherein the isolated T cells are one or both of exhausted and differentiated, and the isolated T cells have antigenic specificity for a tumor-specific antigen expressed by the tumor sample from the mammal, wherein the tumor-specific antigen is a tumor-specific neoantigen or an antigen with a tumor-specific driver mutation; and optionally expanding the numbers of isolated, tumor antigen-specific T cells; and (b) administering to the mammal (i) the isolated T cells of (a) and (ii) a vaccine which specifically stimulates an immune response against the tumor-specific antigen for which the isolated T cells have antigenic specificity.

The invention relates to a method for predicting the evolution of an immune response in a subject towards an effector or suppressor response, based on cellular plasticity determined by the cytokine milieu generated after antigenic stimulation. The invention also allows for evaluating the generation of antigen-specific memory regulatory T cells in the evolution of the immune response. The invention also relates to a kit for carrying out the method according to the invention.

The invention discloses an anti-CD20 antibody or an antigen binding fragment binding to CD20 and application of the anti-CD20 antibody or the antigen binding fragment binding to CD20. After the anti-CD20 antibody and the CD20 antigen binding fragment disclosed by the invention are specifically bound with a CD20 antigen on a cell, immune response is started to mediate B cell dissolution, so that the growth of tumor cells is effectively inhibited or the tumor cells are cleared, and the anti-CD20 antibody and the CD20 antigen binding fragment have a good patent medicine prospect.

A vector harboring nucleic acids encoding a recombinant T cell receptor having antigenic specificity for a DnaJ heat shock protein family member B1-protein kinase cAMP-activated catalytic subunit alpha (DNAJB1-PRKACA) fusion protein is provided, as are host cells and a method for treating fibrolamellar hepatocellular carcinoma with the vector.

Disclosed are methods of isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising: inducing autologous APCs of the patient to present the mutated p53 amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated p53 amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.

Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP and application, and belongs to the field of medical immunology and oncology. The invention relates to a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP. The amino acid sequence of the epitope peptide comprises any one or more of AQFVQEATYK, AQFVQEATYK, AQFVQEATYK and AQFVQEATYK. FLYAPTILLW, FLYAPTILLW; sLLNQHACAV (Solvent Level Normal The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that an anti-tumor immune effect is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for liver cancer, can also be used for preparing quantitative detection reagents for detecting specific T cells of liver cancer related antigen AFP, and have potential application value in prevention, treatment and diagnosis of liver cancer.

The present invention provides a binding protein having antigen specificity for an antigenic peptide / HLA complex, comprising a binding domain containing a T cell receptor (TCR) α chain variable region and a TCR β chain variable region, and uses of the binding protein and pharmaceutical compositions containing the binding protein in the treatment of cancers associated with the antigenic peptide.

The invention discloses a conjugate containing a trehalose derivative and a carbohydrate antigen as well as a preparation method and application of the conjugate, and belongs to the technical field of anti-tumor carbohydrate vaccines. The conjugate is obtained by taking an immunologic stimulant trehalose derivative of a mincle receptor as an embedded adjuvant to be conjugated with a sugar antigen TF, the trehalose derivative can improve the immunogenicity of the TF sugar antigen, the TF sugar antigen is presented to a corresponding immune cell, and a higher-titer immune response aiming at tumor sugar antigen TF specificity is generated. In addition, the compound also has the advantages of clear structure, simple and convenient synthesis method, stable and controllable product quality and the like, and can overcome the defect of weak immunogenicity of sugar antigens; meanwhile, under the action of an embedded adjuvant trehalose derivative, the vaccine can also generate immune memory.

The invention provides an application of a mycobacterium tuberculosis antigen Rv1471 in preparation of drugs or vaccines for preventing and / or treating diseases caused by mycobacterium infection. In a cell model, the antigen Rv1471 can promote the maturation of phenotypes and functions of macrophages, and also can mediate training immunity. On the basis, a subunit protein vaccine for expressing the antigen Rv1471 is further constructed. In a mouse immune model, the immunogenicity of the subunit protein vaccine expressing the antigen Rv1471 in a mouse which is not immunized by BCG is measured, and the subunit protein vaccine can promote antigen-specific T cell immune response. In a cell model and an acute infection mouse model, the antigen Rv1471 can provide an effective protection effect against mycobacterium tuberculosis infection. Therefore, the antigen Rv1471 and the subunit vaccine thereof are expected to become a novel preventive / therapeutic tuberculosis vaccine.

The present invention discloses an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutant human RAS amino acid sequence in which glycine at position 12 is substituted with arginine. Also provided are related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, cell populations, and pharmaceutical compositions. Also disclosed are methods for detecting the presence of cancer in a mammal, and methods for treating or preventing cancer in a mammal.

Disclosed are methods of obtaining a cell population enriched for T cells having antigenic specificity for a cancer-specific mutation using in vitro stimulation of memory T cells. Also disclosed are related methods of isolating a T cell receptor (TCR), populations of cells, TCRs or antigen-binding portions thereof, pharmaceutical compositions, and methods of treating or preventing cancer.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated amino acid sequence encoded by mutated CDKN2A. The TCRs may recognize mutated CDKN2A peptide presented by an HLA-A molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with asp

Disclosed are methods of selectively expanding a number of T cells expressing an exogenous T cell receptor (TCR) having antigenic specificity for a target antigen and methods of selectively expanding a number of T cells each having antigenic specificity for a target antigen. Also disclosed are methods of isolating a T cell receptor (TCR), or an antigen-binding portion thereof, having antigenic specificity for the target antigen; methods of preparing a population of cells that express a TCR, or an antigen-binding portion thereof, having antigenic specificity for a target antigen; methods of preparing a pharmaceutical composition comprising a selectively expanded number of T cells each having antigenic specificity for a target antigen; and methods of treating or preventing a condition in a mammal.

The present invention discloses an isolated or purified T cell receptor (TCR), wherein the TCR has antigen specificity for a mutant human RAS amino acid sequence in which glycine at position 12 is substituted with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal, and methods of treating or preventing cancer in a mammal.